Passage BIO, Inc. 8-K

What Happened
Passage Bio, Inc. filed a Form 8-K on January 12, 2026 to update its corporate presentation and reported a preliminary, unaudited cash, cash equivalents and marketable securities balance of approximately $46 million as of December 31, 2025. The company said this amount is expected to fund operating expenses and capital expenditures into the first quarter of 2027. Passage Bio noted the figure is preliminary and unaudited, may change, and is subject to completion of year‑end financial statements, review procedures and audit.

Key Details

• Preliminary cash, cash equivalents and marketable securities: ~ $46 million (as of Dec 31, 2025).
• Reported runway: expected to fund operations into Q1 2027.
• Date filed/announced: January 12, 2026 (corporate presentation updated and attached as Exhibit 99.1).
• Amount is preliminary and unaudited — subject to final adjustments and audit completion.

Why It Matters
Cash balance and runway are critical for biotech firms that depend on external financing until product revenues exist. The reported ~$46M and stated runway into Q1 2027 give investors a near-term view of funding sufficiency for operations, but the preliminary and unaudited nature means the final audited results could differ. Investors should watch for the finalized year‑end financial statements, any updates to the company’s guidance, and potential financing or cost-management actions if the final cash position or burn rate differs from this preliminary disclosure.